Skip to main content
Fig. 3 | Translational Neurodegeneration

Fig. 3

From: Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer’s pathology

Fig. 3

Competitive receptor binding assay in vitro. NPs reduce the surface active sites of CD36 (a), CD68 (b), SRA1 (c), and (d) TLR2 on the surface of BV2 microglia. BV2 microglia were incubated with NPs for 1 h, then co-incubated with SR-specific antibody or isotype controls for 30 min. After fixation, cells were washed, then blocked with 2% goat serum without PBS-T. To avoid internalization of NPs or antibodies, cells were incubated on ice until imaged. Cells were incubated with secondary antibodies including Alexa 488 or 594 for 1 h at room temperature. Data are presented as mean ± SEM; n = 3; ***P = 0.0001 for a, **P = 0.009 for b, **P = 0.0048 for c, Dunnett’s multiple comparisons shown on graph by one-way ANOVA

Back to article page